CRC Research Update — October 24, 2026
Today's colorectal cancer research highlights
Archive
A collection of 943 issues
Latest
POLE/POLD1 mutations recommended as genomic indicators for immunotherapy in MSS colorectal cancer
Skip to content
The CRC Digest
POLE/POLD1 mutations recommended as genomic indicators for immunotherapy in MSS colorectal cancer
A systematic review of biomarkers for immunotherapy in microsatellite-stable colorectal cancer identified POLE/POLD1 mutations as genomic "hard" indicators recommended by NCCN guidelines, while objective response rates to immune
Lynch syndrome accounts for 6.4% of early-onset colorectal cancer in northern Tanzania
Skip to content
The CRC Digest
Lynch syndrome accounts for 6.4% of early-onset colorectal cancer in northern Tanzania
Among 47 patients aged 50 or younger diagnosed with colorectal cancer in northern Tanzania, three (6.4%) carried pathogenic germline variants consistent with Lynch syndrome, a prevalence comparable to high-income countries.
Hypothesis-generating study explores potential association between intensive long-distance running and advanced adenomas in runners aged 35–50
Skip to content
The CRC Digest
Hypothesis-generating study explores potential association between intensive long-distance running and advanced adenomas in runners aged 35–50
A prospective study of 100 participants who completed at least five marathons or two ultramarathons explored a potential association between intensive long-distance running and advanced adenomas of
Female colorectal cancer survivors more likely to use dietary supplements throughout disease trajectory
Skip to content
The CRC Digest
⚥ SEX & GENDER
Female colorectal cancer survivors more likely to use dietary supplements throughout disease trajectory
A prospective cohort study of 1,934 colorectal cancer survivors found that female and higher educated participants were more likely to use dietary supplements, with 43% reporting use
Chemotherapy-induced apoptotic cell overload drives formation of tumor-suppressive multinucleated giant cells
Skip to content
The CRC Digest
◇ RESEARCH
Chemotherapy-induced apoptotic cell overload drives formation of tumor-suppressive multinucleated giant cells
Researchers found that excessive apoptotic cell burden after neoadjuvant chemotherapy activates the TREM2/TYROBP-MAPK pathway, promoting macrophage fusion into multinucleated giant cells that inhibit tumor growth and reshape the immune microenvironment in
Multiomic profiling identifies FAK, PDK, and proteasome as therapeutic targets in RAS-mutant MSS colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
Multiomic profiling identifies FAK, PDK, and proteasome as therapeutic targets in RAS-mutant MSS colorectal cancer
Analysis of approximately 2,000 tumor samples and 195,246 single cells revealed that focal adhesion kinase, phosphoinositide-dependent kinase, and proteasome inhibition combined with MEK blockade showed activity
AI-assisted colonoscopy improves adenoma detection by 22% in meta-analysis of 46 trials
Skip to content
The CRC Digest
▪ SCREENING
AI-assisted colonoscopy improves adenoma detection by 22% in meta-analysis of 46 trials
A systematic review of 46 randomized controlled trials involving 37,012 participants found that AI-assisted colonoscopy was associated with a 22% relative increase in adenoma detection rate (RR = 1.22, 95%
CRC Research Update — October 23, 2026
Today's colorectal cancer research highlights
KRAS, NRAS, and BRAF mutation frequencies reported in Iranian metastatic CRC cohort
Skip to content
The CRC Digest
KRAS, NRAS, and BRAF mutation frequencies reported in Iranian metastatic CRC cohort
Among 83 patients with metastatic colorectal cancer, mutation frequencies were 47% for KRAS, 14.5% for NRAS, and 6% for BRAF; BRAF mutations were significantly more frequent in patients under 50 years